Document 0660
 DOCN  M9480660
 TI    Emerging indications for octreotide therapy, Part 1.
 DT    9410
 AU    Mosdell KW; Visconti JA; Raabe College of Pharmacy, Ohio Northern
       University.
 SO    Am J Hosp Pharm. 1994 May 1;51(9):1184-92. Unique Identifier : AIDSLINE
       MED/94317668
 AB    Possible new indications for the use of octreotide are discussed. In
       October 1988, octreotide received FDA-approved labeling for use in the
       management of carcinoid syndrome and vipomas. Since that time, research
       results and clinical experience have accumulated that suggest a
       potentially much broader therapeutic role for octreotide. Reports
       continue to be published on the use of octreotide for treating pituitary
       tumors, gastroenteropancreatic tumors, diabetes mellitus,
       AIDS-associated diarrhea, autonomic neuropathy, pancreatitis, pancreatic
       pseudocysts and ascites, complications of pancreatic surgery and
       transplantation, ileostomy-associated diarrhea, enterocutaneous
       fistulas, pancreatic fistulas, dumping syndrome, short bowel syndrome,
       and gastrointestinal bleeding. Other emerging indications for the use of
       octreotide include psoriasis, hypercalcemia, cancer-related pain,
       polycystic ovary syndrome, and certain cancers. In children, octreotide
       has been studied for use in treating hyperinsulinemic hypoglycemia of
       infancy. Along with the common adverse effects of octreotide, such as
       pain at the injection site and nausea, less frequent effects, such as
       cholelithiasis, gallbladder hypercontractility, and gastritis have now
       been described. Much of what has been learned is based on small
       uncontrolled studies and case reports, since the rarity of many of the
       conditions for which octreotide has shown promise has tended to preclude
       larger studies. As clinical experience with octreotide accumulates and
       better-designed trials are completed where possible, a broader
       therapeutic role for octreotide is likely to be recognized.
 DE    Acquired Immunodeficiency Syndrome/COMPLICATIONS  Acromegaly/DRUG
       THERAPY  Diabetes Mellitus/COMPLICATIONS/DRUG THERAPY  Diarrhea/DRUG
       THERAPY/ETIOLOGY  Digestive System Neoplasms/DRUG THERAPY  Human
       Malignant Carcinoid Syndrome/DRUG THERAPY
       Octreotide/PHARMACOLOGY/*THERAPEUTIC USE  Pituitary Neoplasms/DRUG
       THERAPY  Randomized Controlled Trials  Support, Non-U.S. Gov't  JOURNAL
       ARTICLE  REVIEW  REVIEW, TUTORIAL

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).